1. Scrip
  2. >>Therapy Areas

NASDAQ Listing Done, Oculis Eyes Phase III Readouts

Decent Cash Position After SPAC Merger

 
• By Kevin Grogan

Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.

Drops
• Source: Shutterstock: ShutterDivision

Fresh from completing its merger with a special purpose acquisition corporation (SPAC), Oculis S.A. can once again focus on the clinical progress of its eye disease pipeline.

The Swiss biotech says it has completed enrolment for a Phase III trial evaluating OCS-01, a once-daily novel eye-drop formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.